Compare SABR & MRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SABR | MRVI |
|---|---|---|
| Founded | 2006 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 652.0M | 472.8M |
| IPO Year | 2014 | 2020 |
| Metric | SABR | MRVI |
|---|---|---|
| Price | $1.59 | $3.08 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 6 |
| Target Price | $3.70 | ★ $4.00 |
| AVG Volume (30 Days) | ★ 17.7M | 1.2M |
| Earning Date | 05-21-2026 | 05-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 283.56 | 14.29 |
| EPS | ★ 1.34 | N/A |
| Revenue | ★ $3,866,956,000.00 | $185,743,000.00 |
| Revenue This Year | $7.40 | $11.80 |
| Revenue Next Year | $3.26 | $7.74 |
| P/E Ratio | $1.28 | ★ N/A |
| Revenue Growth | ★ 7.46 | N/A |
| 52 Week Low | $0.81 | $1.67 |
| 52 Week High | $3.63 | $4.11 |
| Indicator | SABR | MRVI |
|---|---|---|
| Relative Strength Index (RSI) | 56.52 | 38.72 |
| Support Level | $1.20 | $2.88 |
| Resistance Level | $1.70 | $3.99 |
| Average True Range (ATR) | 0.20 | 0.21 |
| MACD | 0.04 | -0.02 |
| Stochastic Oscillator | 65.13 | 2.91 |
Sabre holds the number-two air booking volume share in the global distribution system industry. The distribution segment represented 80% of total 2025 revenue and airline IT solutions 20% of revenue. The company sold its growing hotel IT solutions division to TPG in 2025 for $960 million in net proceeds. Transaction fees, which are mostly tied to volume and not price, account for the bulk of sales and profits.
Maravai LifeSciences Holdings Inc is a life sciences company that provides critical products that drive the development of groundbreaking vaccines, drug therapies, cell and gene therapies, and diagnostics. The group's solutions empower research into human diseases and support the entire biopharmaceutical development process from early discovery to commercialization. Its reportable segments are Nucleic acid production and biologics safety testing. It generates a majority of its revenue from Nucleic Acid Production and focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, and therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.